va glp 1 study Mapping the effectiveness and risks of GLP-1 receptor agonists Glucagon-like peptide-1 receptor agonists and

NICE guidelines (NG28) recommend blood pressure targets below 140/80 mmHg (or 130/80 mmHg if kidney, eye, or cerebrovascular damage is present) and lipid management according to cardiovascular risk

Our study has limitations

The more oxidative stress (i.e free radical exposure) were under, the more antioxidants including glutathione we need, and we cant always keep up with production

There are 3 ways to take glutathione, of which oral supplementation of up to 500 mg is best

In contrast, GLP-1 injections bypass the digestive system entirely

The mechanism is consistent with general lymphoid tissue growth under elevated IGF-1 exposure